Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Luye Pharma Group's Enterprise Value is €1,361.8 Mil.
Luye Pharma Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €197.4 Mil. Therefore, Luye Pharma Group's EV-to-EBIT ratio for today is 6.90.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Luye Pharma Group's Enterprise Value is €1,361.8 Mil.
Luye Pharma Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €299.0 Mil. Therefore, Luye Pharma Group's EV-to-EBITDA ratio for today is 4.56.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Luye Pharma Group's Enterprise Value is €1,361.8 Mil.
Luye Pharma Group's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was €763.3 Mil. Therefore, Luye Pharma Group's EV-to-Revenue ratio for today is 1.78.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Luye Pharma Group (FRA:LUP) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Luye Pharma Group's current Enterprise Value is €1,361.8 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Luye Pharma Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €197.4 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Luye Pharma Group's current Enterprise Value is €1,361.8 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Luye Pharma Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €299.0 Mil.
Luye Pharma Group's current Enterprise Value is €1,361.8 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Luye Pharma Group's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was €763.3 Mil.
Luye Pharma Group's current Enterprise Value is €1,361.8 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Luye Pharma Group's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was €215.3 Mil.
Luye Pharma Group's current Enterprise Value is €1,361.8 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Luye Pharma Group's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €215.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Luye Pharma Group Enterprise Value Related Terms
Luye Pharma Group Enterprise Value Historical Data
* Premium members only.
The historical data trend for Luye Pharma Group's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Luye Pharma Group's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Luye Pharma Group Enterprise Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Luye Pharma Group's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Luye Pharma Group's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Luye Pharma Group's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of €1,361.8 Mil mean?
Luye Pharma Group (FRA:LUP) has a Enterprise Value of €1,361.8 Mil as of Jul. 03, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Luye Pharma Group and its competitors.
Is Luye Pharma Group's Enterprise Value too high?
Luye Pharma Group's current Enterprise Value is €1,361.8 Mil. Overall, Luye Pharma Group has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Luye Pharma Group's Enterprise Value compare to ZTS and UTHR?
Luye Pharma Group's Enterprise Value of €1,361.8 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Luye Pharma Group and its competitors. Luye Pharma Group's current Enterprise Value is €1,361.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Luye Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, Luye Pharma Group (FRA:LUP) is currently considered Possible Value Trap. The stock's GF Value™ is €0.32, compared to a current price of €0.20 — trading 36.3% below its estimated fair value. The current Enterprise Value is €1,361.8 Mil. Luye Pharma Group's overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Luye Pharma Group (FRA:LUP), the current Enterprise Value is €1,361.8 Mil as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Luye Pharma Group (FRA:LUP) Overvalued in 2026?
Based on GuruFocus' analysis, Luye Pharma Group stock appears to be undervalued.
The current stock price of €0.20 is trading 36.3% below its estimated GF Value™ of €0.32.
GuruFocus considers Luye Pharma Group to be Possible Value Trap.
Key valuation signals for FRA:LUP:
Enterprise Value: €1,361.8 Mil
GF Value™: €0.32 vs. price of €0.20 (36.3% below fair value)
No single metric tells the full story. See the FRA:LUP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Luye Pharma Group Ltd is a China-based drug manufacturer that focuses on development, production, marketing and sale of pharmaceutical products. The company develops drugs related to diagnosing and treating cancer, the cardiovascular system, the alimentary tract, and the central nervous system. The company develops drugs for world-wide use in Asia, Europe, and the United States. The Group organizes its business segments by type of products. Oncology drugs, which derives maximum revenue; Cardiovascular system drugs; Alimentary tract and metabolism drugs; Central nervous system drugs; and others. Geographically, the group derives maximum revenue from Chinese Mainland, while it also has its presence in Asia (other than the Chinese mainland), European Union, and Other countries.
47GF Score
Get the complete analysis for FRA:LUP
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LUP has been successfully added to your 
